Pacific Biosciences Of California (PACB) Operating Leases (2019 - 2026)

Pacific Biosciences Of California has reported Operating Leases for 8 years, with the latest figure at $59.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases rose 11.55% year-over-year to $59.0 million; the trailing twelve-month figure through Mar 2026 stood at $59.0 million (up 11.55% YoY), and the FY2025 full-year result was $56.6 million, up 279.46% from the prior year.
• Operating Leases for Q1 2026 stood at $59.0 million, up from $56.6 million in the prior quarter.
• The five-year high for Operating Leases was $59.0 million in Q1 2026, with the low at $14.9 million in Q4 2024.
• Average Operating Leases over 5 years is $38.9 million, with a median of $40.0 million recorded in 2022.
• Year-over-year, Operating Leases plunged 52.81% in 2024 and surged 279.46% in 2025.
• Tracing PACB's Operating Leases over 5 years: stood at $41.1 million in 2022, then fell by 23.04% to $31.6 million in 2023, then sank by 52.81% to $14.9 million in 2024, then surged by 279.46% to $56.6 million in 2025, then advanced by 4.26% to $59.0 million in 2026.
• The last three Operating Leases figures came in at $59.0 million (Q1 2026), $56.6 million (Q4 2025), and $54.3 million (Q3 2025), per Business Quant data.

Peer Comparison